Two cases of urogenital malignancies in male patients undergoing maintenance haemodialysis

Makita, Yuji; Iwamoto, Toshitaka; Sagiyama, Koji; Nagaoka, Atsuhiro; Kinjo, Manami; Noguchi, Masashi; Aramaki, Kenji; Okuda, Seiya; Fujishima, Masatoshi

doi:10.1007/bf02767729

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although still open to debate, it has been reported that the incidence of malignancy is raised in hemodialysis patients compared to the general population 1–4 . Incidence of prostate cancer in hemodialysis patients has also been the target of debate and the rate of incidence depends on objective groups 2,4 .…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of serum prostate‐specific antigen in hemodialysis patients

Sumura¹,

Yokogi²,

Beppu³

et al. 2003

Int J of Urology

View full text Add to dashboard Cite

Background : The value of serum prostate-specific antigen (PSA) screening was examined to detect prostate cancer in men receiving hemodialysis. Methods : Forty-one male patients age 60-95 (median age, 70 years) receiving hemodialysis were investigated for PSA levels. We set the cut-off point at 4 ng/mL (the usual reference range). Digital rectal examination (DRE) and transrectal ultrasonography (TRUS) of the prostate were performed in patients whose PSA was more than 4 ng/mL and/or who expected further examination of the prostate. When prostate cancer was suspected, biopsy of the prostate was performed. In patients with prostate cancer, magnetic resonance imaging, computed tomography and bone scintigraphy were performed to diagnose the clinical stage. Results : The mean serum level of PSA was 2.10 ± 0.49 ng/mL. In this screening study, four of 41 men required further examinations for prostate cancer. Two of four refused further examinations. The other two were diagnosed with prostate cancer. The incidence of prostate cancer was at least 5% in our hemodialysis patients. One man, whose clinical stage was T2aN0M0, was treated with radical retropubic prostatectomy. Another man, whose clinical stage was T2bN0M0, was treated with luteinizing hormone-releasing hormone analogue. Conclusion : In our preliminary study, prostate cancer screening with PSA was useful for the early detection of prostate cancer in hemodialysis patients. If possible, DRE and TRUS should be performed in conjunction with PSA tests.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of serum prostate‐specific antigen in hemodialysis patients

Sumura¹,

Yokogi²,

Beppu³

et al. 2003

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…In hemodialysis patients, only a few cases of prostate cancer have been reported until recently. [1][2][3][4][5][6][7][8] The present report is probably the first case to show a complete response to lung metastasis of prostate cancer in a hemodialysis patient.…”

Section: Discussionmentioning

confidence: 98%

“…On the other hand, most of the reports emphasized the difficulty of early detection of urogenital malignancies in hemodialysis patients due to a lack of clinical symptoms. [6][7][8] As for prostate cancer in hemodialysis patients, urologic symptoms are considered the same as in general patients. The symptoms of bone metastasis, however, run the risk of being misunderstood as renal-osteo disease in chronic renal failure.…”

Section: Discussionmentioning

confidence: 99%

Prostate cancer with multiple lung metastases in a hemodialysis patient

et al. 2000

View full text Add to dashboard Cite

In hemodialysis patients, few cases of prostate cancer have been reported until recently. We present a case of prostate cancer with multiple lung metastases in a chronic hemodialysis patient. A 65-year-old Japanese man who had maintained hemodialysis for 5 years was referred to our hospital with multiple metastatic lung tumors. Serum prostate tumor markers were highly elevated although his plasma testosterone level was within the normal range. A transrectal needle prostate biopsy confirmed a histologic diagnosis of moderately differentiated adenocarcinoma. Androgen blockade therapy was very effective as evidenced by a quick decrease of serum tumor markers. The followup computed tomography scan of the chest performed 3 months later showed a complete disappearance of the coin lesions. The early detection of prostate cancer in hemodialysis patients is difficult because of a lack of urologic symptoms, which indicate the importance of periodic screening by serum tumor markers. Combined androgen blockade is effective even in hemodialysis patients. However, close follow up is necessary because long-term results and prognoses are still unknown.

show abstract

“…The incidence of prostate cancer in men receiving HD has been a target of debate, and the rate of incidence depends on group definitions [7,8,10] . Prostate cancer is the most common cancer in men and the second leading cause of death from cancer [2] .…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer Screening with Prostate-Specific Antigen in Hemodialysis Patients

Horinaga¹,

Kitamura

Saito

et al. 2007

Urol Int

View full text Add to dashboard Cite

Background/Aims: The diagnostic validity of prostate-specific antigen (PSA) among men receiving hemodialysis (HD) has not been well defined. The aim of this study was to evaluate PSA levels in HD men and to compare them with those of non-uremic controls. Methods: PSA levels were measured in 620 HD men (40–89 years old, mean age 62.4 years). In patients with PSA >4.1 ng/ml, prostate biopsies were performed. Cancer-free men were defined as having PSA ranging between 0 and 4.0 ng/ml, or PSA >4.1 ng/ml but with a pathologically negative biopsy. The resulting data was compared with that for 3,636 non-uremic controls (55–59- (n = 468), 60–69- (n = 2,220), and 70–79-year-old men (n = 948)). Results: Of 45 HD men with PSA >4.1 ng/ml, 22 consented to undergo a biopsy. Ten were positive and 12 were negative. The mean PSA of cancer-free HD men of 50–59 (n = 159), 60–69 (n = 214), 70–79 (n = 116), and 80–89 (n = 30) were 1.0, 1.0, 1.3, and 2.1 ng/ml, respectively. Cancer-free HD men demonstrated significantly lower PSA compared to controls. Conclusions: HD men had lower PSA levels than those of controls.

show abstract

Two cases of urogenital malignancies in male patients undergoing maintenance haemodialysis

Cited by 6 publications

References 11 publications

Diagnostic value of serum prostate‐specific antigen in hemodialysis patients

Diagnostic value of serum prostate‐specific antigen in hemodialysis patients

Prostate cancer with multiple lung metastases in a hemodialysis patient

Prostate Cancer Screening with Prostate-Specific Antigen in Hemodialysis Patients

Contact Info

Product

Resources

About